KORU Medical Systems has partnered with a global pharmaceutical company to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) infusion system. This system will be designed for use with a currently available drug therapy and will involve collaboration with SCHOTT Pharma, utilizing their TOPPAC® prefillable polymer syringes. The project aims to create a platform infusion system compatible with both vials and prefilled syringes.
This development represents a significant advancement in SCIg therapy administration. The planned infusion system addresses a critical need for patients seeking more user-friendly and adaptable home-based treatment options. By simplifying the process and accommodating different drug delivery formats, this system has the potential to improve patient adherence and overall treatment outcomes, a vital consideration for chronic conditions requiring regular SCIg infusions. This collaboration also underscores the growing importance of patient-centric design in drug delivery systems.
The new system will leverage KORU Medical’s existing infusion technology and integrate with SCHOTT’s prefillable syringe technology. This strategic partnership not only expands KORU Medical’s product pipeline but also establishes a potential foundation for future collaborations with SCHOTT Pharma. The integration of prefilled syringes offers a more convenient and potentially safer alternative to traditional vial-based systems, further enhancing the patient experience.
This collaboration positions KORU Medical at the forefront of SCIg infusion technology. The development of a versatile, patient-friendly system could significantly expand market reach and solidify the company’s position as a leader in at-home infusion solutions. The anticipated regulatory clearance and subsequent commercialization of this next-generation system are poised to transform the SCIg landscape and benefit patients seeking improved treatment options.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
